Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma cash
Cash and short-term investments held at the end of each period.
Aytu BioPharma's cash was $26.31M at Jun 30, 2026. For fiscal 2026 it was $26.31M, down 15.0% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $49.90M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $26.31M | -15.0% |
| FY2025 | Jun 30, 2025 | $30.95M | +54.7% |
| FY2024 | Jun 30, 2024 | $20.01M | -13.0% |
| FY2023 | Jun 30, 2023 | $22.99M | +18.7% |
| FY2022 | Jun 30, 2022 | $19.36M | -61.2% |
| FY2021 | Jun 30, 2021 | $49.90M | +3.2% |
| FY2020 | Jun 30, 2020 | $48.33M | +337.6% |
| FY2019 | Jun 30, 2019 | $11.04M | +57.5% |
| FY2018 | Jun 30, 2018 | $7.01M | +699.1% |
| FY2017 | Jun 30, 2017 | $877.54K | -89.1% |
| FY2016 | Jun 30, 2016 | $8.05M | +9.5% |
| FY2015 | Jun 30, 2015 | $7.35M | +394801.2% |
| FY2013 | Aug 31, 2013 | $1.86K | +1608.3% |
| FY2012 | Aug 31, 2012 | $109 | -97.3% |
| FY2011 | Aug 31, 2011 | $3.99K | +158.4% |
| FY2010 | Aug 31, 2010 | $1.55K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $26.31M | -15.0% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $26.72M | +47.0% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $30.03M | +47.2% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $32.63M | +62.3% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $30.95M | +54.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $18.17M | -8.0% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $20.40M | +4.4% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $20.11M | +0.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $20.01M | -13.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $19.76M | +3.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $19.53M | +0.1% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $19.96M | -16.2% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $22.99M | +18.7% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $19.18M | -30.5% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $19.50M | -44.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $23.81M | -40.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $19.36M | -61.2% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $27.61M | -40.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $35.28M | -43.1% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $40.31M | +6.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $49.90M | +3.2% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $46.54M | -25.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $62.03M | +1079.4% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $37.91M | +440.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $48.33M | +337.6% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $62.26M | +325.1% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $5.26M | -70.5% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $7.01M | +76.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $11.04M | +57.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $14.65M | +22.0% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $17.80M | +346.9% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $3.96M | -44.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $7.01M | +699.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $12.01M | +238.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $3.98M | -24.9% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $7.10M | +151.3% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $877.54K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $3.55M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $5.31M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $2.82M | – |
See a number that looks wrong?